TSUMURA & CO. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,800 JPY | +1.20% |
|
+0.61% | +43.05% |
| Sales 2024 * | 153B 978M 1.34B | Sales 2025 * | 184B 1.17B 1.6B | Capitalization | 285B 1.82B 2.49B |
|---|---|---|---|---|---|
| Net income 2024 * | 16.39B 104M 143M | Net income 2025 * | 25.27B 161M 220M | EV / Sales 2024 * | 1.91 x |
| Net Debt 2024 * | 7.4B 47.15M 64.54M | Net Debt 2025 * | 27.26B 174M 238M | EV / Sales 2025 * | 1.7 x |
| P/E ratio 2024 * |
17.4
x | P/E ratio 2025 * |
11.3
x | Employees | 4,032 |
| Yield 2024 * |
1.86% | Yield 2025 * |
2.64% | Free-Float | 90.18% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.20% | ||
| 1 week | +0.61% | ||
| Current month | -0.60% | ||
| 1 month | -0.89% | ||
| 3 months | +42.43% | ||
| 6 months | +44.68% | ||
| Current year | +43.05% |
1 week
3 643.00
3 824.00
1 month
3 643.003 978.00
Current year
2 615.504 082.00
1 year
2 551.004 082.00
3 years
2 536.004 082.00
5 years
2 189.004 200.00
10 years
2 189.004 745.00
| Managers | Title | Age | Since |
|---|---|---|---|
Terukazu Kato
CEO | Chief Executive Officer | 60 | 86-03-31 |
Muneki Handa
DFI | Director of Finance/CFO | 61 | 19-04-30 |
Akito Imada
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenichi Matsui
BRD | Director/Board Member | 74 | 15-05-31 |
Hiroshi Miyake
BRD | Director/Board Member | 74 | 18-05-31 |
Terukazu Kato
CEO | Chief Executive Officer | 60 | 86-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 15 M€ | +11.22% | ||
| 0.04% | 18 M€ | +16.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 3,800 | +1.20% | 299 900 |
| 24-04-26 | 3,755 | +1.49% | 537,300 |
| 24-04-25 | 3,700 | -1.57% | 466,300 |
| 24-04-24 | 3,759 | -0.48% | 370,800 |
| 24-04-23 | 3,777 | -0.45% | 377,500 |
Delayed Quote Japan Exchange, April 30, 2024 at 02:00 am
More quotes
TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3,755
JPY
Average target price
4,920
JPY
Spread / Average Target
+31.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.05% | 1.82B | |
| +26.47% | 664B | |
| +25.70% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +13.42% | 234B | |
| +4.71% | 199B | |
| -10.10% | 196B | |
| -4.04% | 148B |
- Stock Market
- Equities
- 4540 Stock
